|
| Primary information |
|---|
| ID | 10808 |
| Therapeutic ID | Th1188 |
| Protein Name | Hyaluronidase (Human Recombinant) |
| Sequence | NA
|
| Molecular Weight | 61000 |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | Hyaluronidase has a half life of two minutes, but a duration of action of 24-48 hours due to its high potency |
| Description | A purified preparation of the enzyme recombinant human hyaluronidase. Hyaluronidase (Human Recombinant) is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). The purified hyaluronidase glycoprotein contains 447 amino acids with an approximate molecular weight of 61,000 Daltons. |
| Indication/Disease | Indicated as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents. |
| Pharmacodynamics | Hyaluronidase hydrolyzes hyaluronic acid and increase diffusion of injected drugs, thus facilitating their absorption. Hyaluronidase is used for enhancing absorption and distribution of other injected drugs. |
| Mechanism of Action | The family of hyaluronidase enzymes hydrolyzes hyaluronic acid (a glucoseaminoglycan) which is a major constituent of the interstitial barrier. Hyaluronidase (Human Recombinant) is a highly purified recombinant human hyluronidase which lowers the viscosity of the interstitial barrier by breaking down hyaluronic acid and is under investigation as a chemoadjuvant to facilitate local interstitial drug delivery as well as increase bioavilability. |
| Toxicity | Data regarding overdose of hyaluronidase is not readily available.[L13338] In the even of an overdose, treat patients with symptomatic and supportive measures. |
| Metabolism | Data regarding the metabolism of hyaluronidase is not readily available.[L13338] However, protein drugs are expected to be degraded by proteases and other catalytic enzymes to smaller peptides and amino acids.[A182009] |
| Absorption | Data regarding the absorption of hyaluronidase are not readily available due to hyaluronidase being inactivated in blood.[L13338] |
| Data regarding the volume of distribution of hyaluronidase are not readily available due to hyaluronidase being inactivated in blood.[L13338] |
| Clearance | Data regarding the clearance of hyaluronidase are not readily available.[L13338] |
| Categories | NA |
| Patents Number | US7767429 |
| Date of Issue | 8-Mar-2010 |
| Date of Expiry | 23-09-2027 |
| Drug Interaction | NA |
| Target | Hyaluronic acid,Transforming growth factor beta-1 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |